GR
GRI.US GRI Bio Inc.
- Market cap
- USD 3.72M
- P/E
- -
- P/B
- 0.39x
- ROE
- -77.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GRI.US undervalued?
Graham numberThe Graham number of GRI Bio Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GRI Bio Inc. fundamental analysis
No fundamental analysis for GRI Bio Inc. yet.
GRI Bio Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also in…
Full company profileGRI Bio Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GRI Bio Inc. annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 100K | 0.00 | 0.00 | 21.8M | 22.5M | 0.00 | - |
| Gross Profit | -612.00 | -735.00 | 100K | -73.0K | -50.0K | -57.0K | -4.00K | -4.00K | - |
| Operating Income | -4.31M | -3.15M | -1.46M | -1.06M | -2.24M | -11.4M | -8.24M | -12.0M | -6.88M |
| EBITDA | -4.31M | -3.27M | -1.38M | -989K | -2.56M | -11.0M | -8.23M | -12.0M | -6.88M |
| Net Income | -4.31M | -3.46M | -2.53M | -1.56M | -3.22M | -13.0M | -8.21M | -12.0M | -6.86M |
| EPS | -4,840 | -3,888 | -2,841 | -134 | -2,773 | -8,262 | -1.67 | -122 | -3.14 |
| Balance Sheet | |||||||||
| Total Assets | 639K | 4.28M | 955K | 218K | 383K | 2.96M | 5.74M | 8.67M | 9.76M |
| Total Liabilities | 486K | 1.06M | 2.41M | 4.94M | 2.01M | 2.70M | 1.71M | 2.66M | 953K |
| Shareholders' Equity | 153K | 3.21M | -1.45M | -4.72M | -1.63M | 259K | 4.03M | 6.01M | 8.81M |
| Cash & Short-term Investments | 613K | 3.82M | 109K | 90.0K | 9.00K | 1.81M | 5.03M | 8.23M | 9.47M |
| Total Debt | - | 340K | 336K | 3.61M | 673K | 14.0K | 119K | 71.0K | 30.0K |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.37M | -2.88M | -3.71M | -8.31M | -1.09M | -8.99M | -8.61M | -10.2M | 0.00 |
| Capital Expenditure | 2.21K | 5.00 | 2.00K | 0.00 | 3.00K | 8.00K | 0.00 | 3.00K | 0.00 |
| Free Cash Flow | -2.37M | -2.88M | -3.71M | -8.31M | -1.09M | -9.00M | -8.61M | -10.2M | 0.00 |
| Ratios | |||||||||
| ROE | -2,819.8% | -107.8% | - | - | - | -5,033.6% | -203.5% | -199.0% | -77.9% |
| ROA | -674.7% | -81.0% | -265.0% | -715.1% | -839.9% | -441.0% | -143.0% | -138.0% | -70.3% |
| Net Profit Margin | - | - | -2,531.0% | - | - | -59.9% | -36.4% | - | - |
| Debt to Equity | - | 0.11x | - | - | - | 0.05x | 0.03x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GRI Bio Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 2.92M | 1,847 | - |
| 2022 | USD 3.45M | 2,972 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:28 on Jan 26, 2026.
Who owns GRI Bio Inc.
- Insiders 0.38%
- Institutions 6.23%
- Public & others 93.40%
- Shares outstanding 2.19M
- Free float 2.19M
Top funds holding GRI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 9.17K | 0.42% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 872.00 | 0.04% | 0.00% | Sep 2026 |
Top institutions holding GRI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HRT FINANCIAL LLC | 28.8K | 1.32% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 21.4K | 0.98% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 13.9K | 0.63% | -24.78% | Jun 2026 |
| Citadel Advisors Llc | 13.4K | 0.61% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 8.74K | 0.40% | 0.00% | Jun 2026 |
| UBS Group AG | 4.92K | 0.23% | -43.59% | Jun 2026 |
| Tower Research Capital LLC | 2.43K | 0.11% | +129.62% | Jun 2026 |
| Barclays PLC | 83.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
GRI Bio Inc. company profile
- Company name
- GRI Bio Inc.
- Ticker
- GRI.US
- Exchange
- USA Stocks
- Listed since
- Feb 10, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 2223 Avenida de la Playa, La Jolla, CA, United States, 92037
- Phone
- 619 400 1170
- Website
- gribio.com
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Bio Inc. management
4- Dr. W. Marc Hertz Ph.D.Co-Founder, CEO, President & Director · born 1970
- Dr. Vipin Kumar Chaturvedi Ph.D.Co-Founder & Chief Scientific Officer · born 1959
- Ms. Leanne M. KellyCFO & Corporate Secretary · born 1977
- Dr. Albert Agro Ph.D.Co-Founder & Chief Medical Officer · born 1964